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ABSTRACT
Background.Molecular tumor boards (MTBs) provide rational,
genomics-driven, patient-tailored treatment recommenda-
tions. Worldwide, MTBs differ in terms of scope, composition,
methods, and recommendations. This study aimed to assess
differences in methods and agreement in treatment recom-
mendations among MTBs from tertiary cancer referral centers
in The Netherlands.
Materials and Methods. MTBs from all tertiary cancer refer-
ral centers in The Netherlands were invited to participate. A
survey assessing scope, value, logistics, composition, decision-
making method, reporting, and registration of the MTBs was
completed through on-site interviews with members from
each MTB. Targeted therapy recommendations were com-
pared using 10 anonymized cases. Participating MTBs were
asked to provide a treatment recommendation in accordance
with their own methods. Agreement was based on which
molecular alteration(s) was considered actionable with the
next line of targeted therapy.
Results. Interviews with 24 members of eight MTBs rev-
ealed that all participating MTBs focused on rare or com-
plex mutational cancer profiles, operated independently of
cancer type–specific multidisciplinary teams, and consisted
of at least (thoracic and/or medical) oncologists, patholo-
gists, and clinical scientists in molecular pathology. Differ-
ences were the types of cancer discussed and the methods
used to achieve a recommendation. Nevertheless, agree-
ment among MTB recommendations, based on identified
actionable molecular alteration(s), was high for the 10 evalu-
ated cases (86%).
Conclusion. MTBs associated with tertiary cancer referral
centers in The Netherlands are similar in setup and
reach a high agreement in recommendations for rare or
complex mutational cancer profiles. We propose a
“Dutch MTB model” for an optimal, collaborative, and
nationally aligned MTB workflow. The Oncologist
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Cancer Diagnostics and Molecular Pathology
Implications for Practice: Interpretation of genomic analyses for optimal choice of target therapy for patients with cancer is
becoming increasingly complex. A molecular tumor board (MTB) supports oncologists in rationalizing therapy options. How-
ever, there is no consensus on the most optimal setup for an MTB, which can affect the quality of recommendations. This
study reveals that the eight MTBs associated with tertiary cancer referral centers in The Netherlands are similar in setup
and reach a high agreement in recommendations for rare or complex mutational profiles. The Dutch MTB model is based
on a collaborative and nationally aligned workflow with interinstitutional collaboration and data sharing.
INTRODUCTION
The emergence of DNA- and RNA-based molecular cancer
profiling techniques for predictive testing in the routine diag-
nostic setting has rapidly expanded the diagnostic guidance
for targeted therapies [1]. Molecular tumor boards (MTB)
support treating physicians in understanding the increasing
complexity of molecular testing results, providing rational,
genomics-driven, patient-tailored treatment recommenda-
tions with respect to the currently available targeted drugs
[2, 3]. MTBs are hosted in cancer centers that offer extensive
molecular profiling techniques [4–18]. Although the MTBs
that have thus far published their methods all focus on trans-
lating molecular testing results into a therapeutic recommen-
dation, there are major differences in terms of scope,
composition, and methods [2, 3]. Notably, treatment recom-
mendations provided by MTBs seem to vary widely. A recent
comparison of five independent MTBs from four countries
revealed that only two of five MTBs provided similar recom-
mendations for four fictional cases with complex mutational
profiles [19]. Regional and international differences in com-
position and logistics [2], method and prioritization [19],
access to targeted drugs [3, 16], and molecular diagnostic
workup [2] are potential sources of heterogeneity.
The incorporation of MTBs into standard-of-care cancer
diagnostics necessitates mitigation of heterogeneity in MTB
recommendations. Although perfect agreement in treatment
recommendations may not be achievable because they are tai-
lored to the patient at hand and dependent on drug and trial
availability, discrepancies in target identification might be
averted. For this purpose, the Predictive Analysis for Therapy
project was initiated, which aims to optimize patient access
to personalized cancer therapy in The Netherlands [20]. This
includes optimizing MTBs by providing directives on the mini-
mal requirements for hosting an MTB and achieving a recom-
mendation, promoting the exchange of knowledge among
MTBs through a shared database, and ensuring accessibility
to MTBs for community hospitals and laboratories.
To identify the prerequisites for reaching a well-informed
MTB recommendation, this study aims to assess current simi-
larities and differences in MTB methods and, secondly, to
determine agreement in treatment recommendations among
MTBs from tertiary cancer referral centers.
MATERIALS AND METHODS
MTBs Included in Analysis
MTBs associated with tertiary cancer referral centers were
identified through a digital survey among all Dutch
molecular pathology laboratories. MTBs from all academic
medical centers and one nonacademic tertiary cancer refer-
ral center were invited to participate.
Assessment of Similarities and Differences Between
MTB Methods
All MTBs were invited to engage in one or more on-site inter-
views. A survey to assess similarities and differences among
MTBs was designed, covering scope and perceived value,
logistics and composition, decision-making method, reporting,
and registration of MTB cases, and the interviewees’ view on
harmonization and collaboration among MTBs (supplemental
online Methods). The MTBs were asked to select inter-
viewees representing multiple disciplines active in their MTB.
Interviews and attendances of MTBs were performed by a
medical researcher (B.K.) between June and September 2019.
All interviewees consented to participation.
Comparison of Targeted Therapy Recommendations
MTB recommendations were compared using 10 cases repre-
sentative of the MTBs’ setting in terms of cancer type, muta-
tional profile, and inquiry. The participating MTBs were asked
to submit an anonymized case (supplemental online Methods).
The submitted cases were adjusted for further anonymization
and formatting. Finalized cases were prepared as two-page
documents (example provided in the supplemental online
Methods).
From September 26 until November 21, 2019, 10 cases
were sent to participating MTBs. The MTBs were asked to
handle these as routine MTB requests and provide recom-
mendations according to their usual method. After the ini-
tial round, two cases with low rates of agreement with
respect to the choice of inhibitor or its timing of use were
selected. These cases were sent for a second time to the
participants along with the recommendations received in
the initial round for those cases, in a blinded fashion. The
participating MTBs were asked if they would revise their ini-
tial answer when presented with the other MTBs’ recom-
mendations and provide arguments for their decision.
The research ethics board of the department of Pathology
at the University Medical Center Groningen (UMCG) approved
the use of anonymous case descriptions for this study. The
study protocol was consistent with the UMCG Research Code
and national ethical and professional guidelines [21, 22].
Statistical Analysis
Descriptive statistics are provided. The consensus for a case
was defined as the most frequently provided recommenda-
tion. Agreement was measured by the percentage of MTBs
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that provided a recommendation in accordance with this
consensus. Agreement among MTB recommendations was
based on which molecular alteration(s) was considered
actionable with the next line of targeted therapy (next action-
able target). The agreement rate was calculated from the ini-
tial recommendations.
Table 1. MTB demographics as attained by on-site interviews
Demographic MTBs, n (%)
MTBs participating in the on-site interviews 8 (100%)
Type of hospital that the MTB is associated with
University medical center (academic) 7 (87.5)
Nonacademic tertiary cancer referral hospital 1 (12.5)
Year in which the MTB was established
2014 (active for 6 years) 1 (12.5)
2015 (active for 5 years) 3 (37.5)
2016 (active for 4 years) 2 (25)
2017 (active for 3 years) 2 (25)
Cancer types eligible for review by the MTB
Any type of cancer 5 (62.5)
Thoracic oncology 3 (37.5)
Frequency of MTB meetings
MTB meets once every week 4 (50)
MTB meets once in every 2 weeks 4 (50)
Internal reporting of recommendation
Report in the patient’s electronic health record 7 (87.5)
Recommendation is included in the pathology report 1 (12.5)
Communication of recommendation to external applicants
Directly to applicant (videoconferencing, e-mail, telephone call) 5 (62.5)
By means of a medical letter 2 (25)
Directly to applicant by videoconferencing and through pathology report 1 (12.5)
Registration of cases reviewed by the MTB
Cases, recommendations, and follow-up are registered in a local database 2 (25)
Only basic case information is registered in a local database 2 (25)
No registration in local database 4 (50)
Regional collaboration by the MTB
Cases from peripheral hospitals are reviewed 7 (87.5)
Cases from other tertiary cancer referral centers are reviewed 2 (25)
External specialists attend MTB meetings through videoconferencing 4 (50)
Experts participating in MTB meetings
Clinical scientists in molecular pathology 8 (100)
Pathologists 8 (100)
Thoracic oncologists 8 (100)
Medical oncologists 5 (62.5)
Postdocs, PhD students, researchers 5 (62.5)
Clinical geneticists 3 (37.5)
Clinical chemists 2 (25)
Laboratory technicians 2 (25)
Hemato-oncologists 1 (12.5)
Nurse practitioners 1 (12.5)
Pharmacists 1 (12.5)
Radiation oncologists 1 (12.5)
Structural biologists 1 (12.5)
Abbreviation: MTB, molecular tumor board.
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RESULTS
MTBs Included in the Analysis
MTBs from all eight Dutch tertiary cancer referral centers were
included, representing Amsterdam University Medical Centers,
Erasmus Medical Center, Leiden University Medical Center,
Maastricht University Medical Center, Netherlands Cancer
Institute, Radboud University Medical Center, University Medi-
cal Center Groningen, and University Medical Center Utrecht.
On-site interviews were held with 24 MTB members: nine clin-
ical scientists in molecular pathology (CSMPs), six pathologists,
five thoracic oncologists, two medical oncologists, and two
(bio)medical researchers. Meetings of MTBs were attended
when this could be combined with the on-site interview.
Figure 1. Online information resource usage for MTB decision making. Bar graphs depicting the usage of online resources for deci-
sion making within MTBs. A survey was filled in by representatives of seven MTBs. (A): Data- and knowledge bases for somatic vari-
ant calling and/or interpretation. (B): Data- and knowledge bases for germline variant calling and/or interpretation. (C): Online
resources for genomic sequences. (D): Online resources for scientific literature. (E): Online resources for oncology guidelines. (F):
Trial registries.
Abbreviations: CIViC, Clinical Interpretation of Variants in Cancer; COSMIC, Catalogue of Somatic Mutations in Cancer; dbSNP, Short
Genetic Variations database; DGIdb, Drug Gene Interaction Database; ESMO, European Society for Medical Oncology; ExAC, Exome
Aggregation Consortium; JAX CKB, the Jackson Laboratory Clinical Knowledge Base; OncoKB, Precision Oncology Knowledge Base;
PCT MD Anderson, Personalized Cancer Therapy Knowledge Base; MTB, molecular tumor board.
© 2020 The Authors.
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Figure 2. The Dutch MTB model. Flow diagram depicting an optimal MTB workflow as recommended by the eight molecular tumor
boards participating in this study. Responsibilities of each party are annotated for external (gray) or MTB-associated (black) physi-
cians/oncologists (stethoscopes) and CSMPs/pathologists (microscopes). All four parties can submit molecular-oriented questions
about their cases to the MTBs. The MTB-associated oncologist is responsible for the clinical case preparation, and the CSMP and
pathologist are jointly responsible for characterization of the molecular profile. During review in an MTB meeting, a diagnostic
and/or therapeutic recommendation is formulated, which is communicated to the requestor, recorded in the patient’s electronic
health record, and registered in a local database. The requestor can then use this recommendation in their choice of (molecular)
tests or (targeted) therapy. aIn case of biomarkers with both germline and somatic implications, attendance of a clinical geneticist
is recommended. In case of discussing whole-exome or whole-genome sequencing results, attendance of a bioinformatician is rec-
ommended.
Abbreviations: CSMP, clinical scientist in molecular pathology; MTB, molecular tumor board.
© 2020 The Authors.
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Assessment of Similarities and Differences Between
MTB Methods
Scope and Value of the MTBs
The eight MTBs were founded between 2014 and 2017
(Table 1). Reciprocal improvement of expertise for attendees
was considered a core value of an MTB and an important
reason for founding MTBs. The MTBs reviewed cases with
molecular-oriented questions, such as the clinical conse-
quences of molecular findings, the availability of therapeutic
options, or the most appropriate test(s) to perform for a
case. Seven MTBs reviewed only selected rare or complex
cases (two to eight cases average per meeting); one MTB
reviewed all molecular testing results (estimated 5–15 cases
per meeting). The most common molecular findings eligible
for review included somatic mutations, copy number vari-
ants, and fusion genes detected by targeted panel next-
generation sequencing, fluorescence in situ hybridization,
immunohistochemistry, or RNA-based fusion transcript analy-
sis. Results from whole-genome sequencing (WGS) or whole-
exome sequencing (WES) were uncommon, as these
methods were not used routinely at the time of this study,
although all MTBs were open to interpret these results.
Five MTBs reviewed any type of cancer (“cancer agnos-
tic”), whereas three MTBs only reviewed thoracic oncology.
Thoracic oncology cases were most common in six MTBs
because of the diversity of relevant actionable biomarkers
and because the Dutch national guideline for non-small cell
lung cancer (NSCLC) recommends referral to an MTB in case
of rare mutational profiles [23]. The most common reason
for reviewing other cancer types was to assess eligibility for
trials such as the Drug Rediscovery Protocol (DRUP) [24].
All MTBs took place as individual meetings, outside of
conventional, cancer type–specific multidisciplinary team
(MDT) meetings. Differentiation between primary treatment
modalities was considered the responsibility of the conven-
tional MDT, whereas MTBs were considered more proficient
in guiding decision making on the most appropriate treat-
ment when targetable alterations are present. Two thoracic
oncology MTBs were hosted sequentially with a conventional
MDT, selecting cases for either meeting depending on the
cancer stage. Six MTBs were not tuned to conventional
MDTs, although attending oncologists and pathologists were
also involved in conventional MDTs.
Logistics and Composition of the MTBs
In all MTBs, cases could be submitted by the treating physi-
cian, CSMP, or pathologist. Participants in all MTBs included
oncologists (thoracic, medical, or hemato-oncologists,
depending on the cancer type reviewed), CSMPs, and
pathologists. Other common attendees were (bio)medical
researchers (five MTBs) and clinical geneticists (three MTBs,
of which two consulted geneticists on request) (Table 1).
Seven MTBs received inquiries from peripheral hospitals or
pathology laboratories, of which four facilitated attendance
of external specialists through videoconferencing.
Decision-Making Method of the MTBs
In preparing a case, a variety of (online) resources were con-
sulted (Fig. 1). Nine resources were used by all MTBs: the
1000 Genomes Browser [25], cBioPortal [26], ClinVar [27],
COSMIC [28], dbSNP [29], Ensembl [30], JAX-CKB [31],
OncoKB [32], and PubMed [33]. Trial overviews were not sys-
tematically consulted prior to the MTB meetings because of
time restrictions. In some MTBs, dedicated trial-coordinating
oncologists were consulted after evaluation of actionability
by the MTB. Interviewees regarded awareness of the trial
availability variable and dependent on which oncologist(s)
attended meetings.
The MTBs served as a unifying platform to achieve a
profile-based, patient-tailored consensus recommendation
based on the identification/prioritization of genomic alter-
ations and potential drug actionability (prepared by CSMPs/
pathologists) and the assessment of availability of clinical
trials or compassionate use drugs for eligible patients (pre-
pared by oncologists). A recommendation could be diagnos-
tic (such as which additional tests to perform), therapeutic,
or both (Fig. 2).
Reporting and Registration of MTB Cases
For reviewed cases, MTBs created a report in the individual
patient’s electronic health record (seven MTBs) or in the
pathology report (one MTB). Recommendations to external
applicants were communicated through videoconferencing,
e-mail, an official written letter, or the pathology report.
Four MTBs maintained a local database for registration of
new cases and searching prior cases.
View on Harmonization and Collaboration
Between MTBs
Two MTBs occasionally received inquiries from other ter-
tiary referral centers harboring an MTB. As personal experi-
ence with a similar case, including treatment results, was
considered an important factor in rationalizing a recom-
mendation, facilitation of access to data on comparable
cases from other MTBs was acknowledged as a valuable
addition to their toolset.
Comparison of Targeted Therapy Recommendations
All eight MTBs participated in a study to compare MTB rec-
ommendations based on a selection of anonymized cases.
Each MTB submitted one case description. The composition
of cases was based on information gathered in the inter-
views: six NSCLC cases, two melanoma cases, one colorectal
cancer (CRC) case, and one gastrointestinal stromal tumor
(GIST) case (supplemental online Table 1).
As three MTBs were restricted to thoracic oncology,
68 answers were expected (six NSCLC cases with eight
responses each and four non-NSCLC cases with five answers
each). One MTB was unable to review the last three non-
NSCLC cases because of lack of availability of a medical
oncologist, leaving 65 responses eligible for analysis.
Agreement Between MTB Recommendations
The agreement between MTBs in identifying the foremost
actionable target ranged between 60% and 100% (Table 2).
Seven of eight MTBs (87.5%) identified BRAF/MEK as
actionable targets in case 1A (osimertinib-resistant NSCLC,
resistance by BRAF p.(V600E)). The majority of MTBs rec-
ommended osimertinib/dabrafenib/trametinib combination
© 2020 The Authors.
The Oncologist published by Wiley Periodicals LLC on behalf of AlphaMed Press.








































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































© 2020 The Authors.
The Oncologist published by Wiley Periodicals LLC on behalf of AlphaMed Press.
www.TheOncologist.com
Koopman, Groen, Ligtenberg et al. 7
therapy. In case 1B (CRC, KRAS p.(L19F)), all five MTBs
agreed that the mutation could potentially inhibit response
to anti-EGFR antibodies, but only three MTBs (60%) consid-
ered the evidence sufficient to recommend against anti-
EGFR antibodies.
For case 2A (melanoma, mutations in BRAF, NRAS, and
CDKN2A), three of four MTBs (75%) recognized CDK4/6 as
actionable targets of palbociclib within the DRUP trial
(if CDKN2A biallelic inactivation was proven). Two MTBs rec-
ommended immunotherapy first, in line with the national
NSCLC guideline. In case 2B (NSCLC, mutations in EGFR and
ERBB2), six of eight MTBs (75%) acknowledged the potential
inhibitory effect of afatinib on cancers harboring the ERBB2
mutation—thus identifying both EGFR and ERBB2 as action-
able by afatinib—although one MTB recommended chemo-
therapy prior to treatment with afatinib.
In case 3A (osimertinib-resistant NSCLC, resistance cau-
sed by a TRIM24-BRAF fusion), seven of eight MTBs (87.5%)
recognized MEK as a target. The majority of MTBs rec-
ommended osimertinib/trametinib combination treatment.
Case 3B (CRC, ERBB2 amplification) achieved 100% agree-
ment: inclusion in the DRUP trial for treatment with anti-
ERBB2 antibodies.
One hundred percent agreement was also achieved for
case 4A (GIST, BRAF p.(V600E)): inclusion in the DRUP trial
for treatment with BRAF/MEK inhibition. In case 4B (NSCLC,
mutations in KRAS, BRAF, CDKN2A, and the TERT promoter
region), seven of eight MTBs (87.5%) did not identify a tar-
get. Only one MTB commented on the potential actionability
of the BRAF non-V600 mutation with a MEK inhibitor in a
late line of treatment. Seven MTBs recommended immuno-
therapy or chemotherapy combined with immunotherapy, all
noting the omitted PD-L1 status.
For case 5A (osimertinib-resistant NSCLC, mutations in
EGFR and TP53 and amplification of MET and EGFR), seven
MTBs (87.5%) acknowledged MET as the actionable target in
the next or subsequent line of targeted treatment. However,
the prioritization of treatment options varied, with some
MTBs preferring exhaustion of treatment options with che-
motherapy and disagreement on continuation of EGFR inhi-
bition. In case 5B (ALK inhibitor–resistant NSCLC, ALK fusion,
ALK p.(G1202R)), all MTBs (100%) acknowledged that ALK
was still actionable with a third-generation ALK inhibitor.
Lorlatinib was recommended by seven of eight MTBs.
Overall, among 65 MTB recommendations on the fore-
most actionable target for these 10 representative cases,
the overall agreement was 86% (56 of 65 responses) after
the first round of recommendations.
Revision of Cases with a Low Rate of Agreement
Of cases with responses from all MTBs, 2B and 5A had the
lowest rates of agreement with respect to the choice of
inhibitor or its timing of use. These cases were sent back to
the MTBs along with the other (blinded) MTBs’ recommen-
dations. For case 2B (NSCLC, mutations in EGFR and ERBB2),
two MTBs changed their answer based on the other MTBs’
motivations, acknowledging the provided evidence for
targeting ERBB2 with afatinib. For case 5A (NSCLC with muta-
tions in EGFR and TP53 and amplifications ofMET and EGFR),
















































































































































































































































































































































































































































































































































































































































































































© 2020 The Authors.
The Oncologist published by Wiley Periodicals LLC on behalf of AlphaMed Press.
Molecular Tumor Boards in The Netherlands8
of EGFR with osimertinib with its previous recommendation
for targeting MET. In addition, one MTB changed its answer
because a trial combining osimertinib with MET inhibitor
tepotinib had opened in its center.
In total, four MTBs changed their initial answer for case
2B or 5A, either based on evidence provided by other MTBs
or because new center-specific treatment possibilities had
become available.
DISCUSSION
This study describes similarities and differences between
eight MTBs from tertiary cancer referral centers in The
Netherlands. Despite differences in terms of scope and
methods, MTBs had similar compositions of experts and
reached a high level of agreement in identifying actionable
targets. Based on these results and the perspectives of par-
ticipating MTBs, a consensus was formed on an optimized,
collaborative workflow for an MTB hosted by a tertiary can-
cer referral center (Fig. 2). This workflow, which we desig-
nated the “Dutch MTB model” (Table 3), integrates the
similarities identified in this study and was approved by rep-
resentatives of the eight participating MTBs.
One of the MTBs from this study had previously published
on the treatment outcome resulting from their workflow [4].
Several individual MTBs in other countries have also reported
their scope, methods, recommendations, and treatment out-
comes [5, 7–18]. Comparing these MTBs, the scope and
observed value of an MTB, as well as its place within the
health care process, vary. Some MTBs assess eligibility for clini-
cal trials [5]. Others also include surgeons, radiation oncolo-
gists, and radiologists and are effectively expanded
conventional MDTs [8, 16]. In this setup, complex molecular
cases are discussed in addition to the nonmolecular cases typi-
cally discussed in conventional cancer type–specific MDTs.
MTBs adhering to the Dutch MTB model, however, review
(complex) molecular cases only, differentiate between treat-
ment options based on molecular alteration(s), and indicate
whether the provided (targeted) therapy recommendation is
standard of care, within a clinical trial, or off label. This is simi-
lar to other previously published MTBs [4, 6, 7, 9, 10, 13, 15,
18]. The main reason for not incorporating complex molecular
results into an “enhanced” conventional MDT is the highly
specialized and complex nature of the MTB. A low case load,
enabled by selectivity in the cases that are discussed, allows
time to elaborately discuss biological and clinical consequences
of molecular results for a patient. This leads to a reciprocal
improvement of expertise of all parties involved on the clinical
consequences of molecular test results and the biological
rationalization of targeted therapy options. In addition, the
possibility to organize an MTB in a cancer-agnostic fashion
allows for the interdisciplinary exchange of molecular diagnos-
tic and therapeutic knowledge, as well as the proper assess-
ment of eligibility for trials that are not limited to a single type
of cancer.
The Dutch MTB model encompasses a comprehensive
approach toward a case, featuring the identification/priori-
tization of genomic alterations, potential drug actionability,
assessment of drug availability, and the patient’s eligibility
for a targeted treatment (Fig. 2). MTBs feature experts that
are directly involved in differentiation between targeted
therapy options: oncologists (thoracic, medical, or hemato-
logical, depending on the cancer type discussed),
molecular-oriented pathologists, and CSMPs. These are con-
sidered the minimal attendees for reaching a consensus
expert recommendation. Treating physicians, pathologists,
and CSMPs can all submit cases. The CSMP has an essential
role with the primary responsibility to interpret genomic
variants in routine molecular diagnostics [34]. The atten-
dance of CSMPs is a major distinguishing factor from con-
ventional MDTs, which was also the case for multiple
previously published MTBs [9–12, 14, 16–18].
In addition to these three core members, a majority of
previously published MTBs also incorporate geneticists or
bioinformaticians [5, 7, 8, 10–17]. In a previous effort to
assess differences between MTBs in The Netherlands,
attendance of geneticists and bioinformaticians was rec-
ommended when discussing large-scale sequencing results,
such as WES and WGS [2]. However, geneticists were mem-
bers of only three out of eight MTBs in our study, and
bioinformaticians were absent. This is because current
MTBs rarely discuss WES/WGS, as these techniques are at
present not performed in routine molecular diagnostics.
Thus, although geneticists and bioinformaticians are valu-
able, we do not currently consider them mandatory. For
now, consultation on demand is deemed sufficient, unless
the MTB frequently reviews biomarkers with germline
implications, such as BRCA1 and BRCA2 (geneticists), or
Table 3. Definition of a molecular tumor board according to
the Dutch MTB model
A An MTB is the primary source of information for
interpreting (rare or complex) molecular diagnostic results
in oncology and serves as a reciprocal educative platform
for clinicians, oncologists, and molecular pathology
specialists.
B An MTB focuses on differentiating between targeted
therapeutic options (standard of care, within a clinical trial,
or off label) or other therapeutic options based on
molecular diagnostic results.
C An MTB can be cancer agnostic and operates
independently of the conventional cancer type–specific
MDTs but features oncologists and pathologists who also
participate in conventional MDTs.
D An MTB features at least (a) oncologists (thoracic, medical
or hematological, depending on the type of cancer
discussed), (b) (molecular-oriented) pathologists, and (c)
clinical scientists in molecular pathology. A clinical
geneticist is recommended in case of discussing
biomarkers with both germline and somatic implications.
E An MTB is hosted in a tertiary cancer referral center and is
open for participation by experts from peripheral hospitals
and pathology laboratories, preferably with access through
videoconferencing. It is a responsibility of the MTB’s
network to ensure that all patients in its region have
access to an MTB recommendation.
F An MTB ensures its recommendation is accessible in the
patient’s electronic health record.
G An MTB maintains a local registry of reviewed cases,
preferentially with systematic follow-up of cases within the
MTB to evaluate effectiveness of the recommendations.
Abbreviations: MDT, multidisciplinary team; MTB, molecular tumor
board.
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biomarkers detected with WES/WGS such as complex geno-
mic rearrangements (bioinformaticians).
Assessment and Harmonization of MTB
Recommendations
Although our results reveal some differences in the methods
used to reach a recommendation, all MTBs operate in accor-
dance with the Dutch MTB model presented here. To evaluate
the agreement in treatment recommendations from MTBs
adhering to the Dutch MTB model, we compared recommen-
dations provided for 10 typical complex MTB cases. A prior
study by Rieke and colleagues used a comparable setup, com-
paring five MTBs from four countries based on four fictional
cases [19]. The authors found a poor agreement, with compa-
rable recommendations from two out of five MTBs (40%) for
three cases and three out of five MTBs (60%) for one case.
The authors attributed this heterogeneity to differences in
interpretation of tumor and germline aberrations and stan-
dards of prioritization. The higher overall rate of agreement in
our study may in part be explained by a lower number of
alterations than was observed in the study of Rieke et al., who
included more unknown alterations and had an average of
8 alterations compared with 2.6 in our study [19]. In addition,
our comparison was performed with MTBs within the same
health care system and thus subject to the same rules and
regulations with respect to the availability of drugs. Molecular
pathology laboratories associated with these MTBs were
already collaborating in a national consortium to achieve uni-
formity in the interpretation of genomic aberrations in cancer
[20] and are unified in The Netherlands Society for Pathology
[35]. Dutch thoracic oncologists and medical oncologists col-
laborate within respective professional networks [36, 37].
These networks have long histories of collaborating in devel-
oping national guidelines, organizing joint educational and
consensus meetings, and shared national training programs. A
Dutch MTB is thus effectively a meeting of local experts rep-
resenting these existing cooperative efforts. We consider this
combination of national connection and interpretative kinship
through close collaboration among tertiary cancer referral cen-
ters a key factor in achieving optimal diagnostic and/or thera-
peutic recommendations with a high agreement.
In calculating agreement, we considered recommenda-
tions comparable based on the next identified actionable
target. This is because differentiating between treatment
options based on molecular alterations is the core task of
an MTB distinguishing it from conventional MDTs. Our com-
parison revealed that the MTBs were generally able to inde-
pendently gather the available evidence on a molecular
aberration (Table 2). Yet, access to the same evidence does
not necessarily lead to identical recommendations: for
example, three of five MTBs cited two preclinical studies on
the relatively rare KRAS p.(L19F) mutation (case 1B) [38,
39], but one out of these three did not regard the evidence
sufficient to recommend against anti-EGFR antibodies. This
translates to an inevitable limitation in agreement rates
between MTBs, as the role of the MTB is to interpret the
available evidence and weigh this against patient factors,
guidelines, rules and regulations, and the availability of
therapeutic choices. Continuous access to and revision of
the new scientific evidence is imperative to an adequate
performance of MTBs. We consider data sharing between
MTBs and regularly comparing treatment recommendations
for specific complex cases key in achieving this.
The final treatment recommendations (Table 2) were
more heterogeneous than represented by the calculated
agreement for the identification of the next actionable tar-
get for three major reasons. First, the prioritization of
targeted therapy versus other treatment options differed:
in cases 1A, 2A, 2B, and 5A, several MTBs recommended
nontargeted treatment modalities prior to targeted therapy.
Second, there were differences in the exact inhibitor rec-
ommended. Drugs were available both within or outside of
clinical trials (for example, ALK inhibitors in case 5B), and
MTBs tended to recommend the trial available in their own
centers. Finally, there were slight differences in whether or
not to combine treatments when multiple alterations could
be targeted (cases 3A and 5A). Considering our proposed
definition of an MTB as primarily responsible for differentia-
tion between targeted therapeutic options (Table 3), the
last difference is most significant to address. A revision for
two cases (2B and 5A) revealed that MTBs are adaptable
when presented with new evidence: four MTBs revised
their recommendations based on evidence provided by
other MTBs. In case 5A, specifically, the MTB not suggesting
combination treatment changed its recommendation when
presented with the recommendations of the other MTBs.
Thus, the rate of agreement between MTBs may be
improved by ensuring MTBs maintain local databases of
reviewed cases, preferentially with systematic follow-up of
cases, and sharing exceptional cases with other MTBs in a
secure database to allow exchange of knowledge [20, 40].
We used cases submitted by the MTBs to ensure a repre-
sentative case mix routinely discussed by Dutch MTBs. As the
MTBs had all been incorporated into the routine diagnostic
setting of their respective institutions, the selected cases rep-
resented cancer types with established benefit of targeted
molecular testing. In other words, these MTBs primarily facili-
tate expansion of “established” precision oncology programs,
with a greater chance of alterations that may be targeted with
off-label therapy, in compassionate use or in clinical trials. In
contrast, MTBs focusing on discovering novel treatment
options with pancancer WES or WGS primarily facilitate
“explorative” precision oncology programs. In these MTBs, the
discussed cases harbor more alterations with unknown signifi-
cance, decreasing the chance of benefit for patients. Ideally,
an MTB should encompass both types of programs.
Further improvement in the Dutch MTB model may be
especially gained by achieving homogeneity in gathering
the increasing variant-level evidence to explore treatment
options based on the molecular profile. This includes grad-
ing the actionability of variants, for which various classifica-
tion systems have been proposed [41–43], and access to
knowledge bases such as cBioPortal [26], JAX-CKB [31], and
OncoKB [32]. Grading of actionability was not standard pro-
cedure for participating MTBs and thus not analyzed. This is
a limitation of the current Dutch MTB model, and efforts
are ongoing to harmonize the classification of pathogenicity
and actionability in The Netherlands. Steps requiring har-
monization include how to distinguish germline variants
from somatic variants, how to interpret variants of
© 2020 The Authors.
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unknown significance, which variant-level data- and knowl-
edge bases need to be consulted to identify potential treat-
ment options, which classification system(s) to apply, and
exact criteria for allocating variants to the different classes.
CONCLUSION
This study shows that the eight Dutch MTBs reach targeted
therapy recommendations in high agreement even with differ-
ences in scope, logistics, and methods. A high agreement (86%)
was achieved especially in identifying the principal actionable
targets for cases with rare or complex molecular testing results.
Regional connection and data sharing among MTBs and inter-
pretative kinship through collaboration among pathology
departments were identified as key factors to achieve a high
rate of agreement between MTB recommendations. An MTB,
although hosted in a tertiary cancer referral center, should be
accessible for all patients with cancer, which requires active par-
ticipation of health care professionals from peripheral hospitals
and pathology laboratories in a regional MTB network. We rec-
ommend using our proposed Dutch MTB model for an optimal,
collaborative, and nationally aligned MTB workflow to trans-
form precision medicine from retrospective anecdotal evidence
to successful prospective evidence.
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